CA-USERTESTING
13.7.2022 15:02:08 CEST | Business Wire | Press release
UserTesting (NYSE: USER), a leader in video-based human insight , today announced advanced Instant Insight features, powered by machine learning, to help companies expedite the analysis of human insights at the test-level and accelerate time to insights. Using data-automation and proprietary models, the UserTestingⓇ Human Insight Platform can detect patterns and anomalies in the customer data, and automatically surface high-value insights within the Customer Experience Narratives. The latest product updates are designed to help companies uncover key customer perspectives more quickly, so team members can understand where to focus their efforts for greater success. In addition to English and German, UserTesting is now available in French, and customers can test in the French language with access to French speaking contributors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005310/en/
New features in this product release:
Discover Patterns and Key Customer Takeaways More Quickly with Test-Level Instant Insights
UserTesting’s test-level Instant Insight feature utilizes data-driven automation and machine learning models to accelerate post-test analysis by automatically detecting patterns, anomalies, and key insights within customer data across multiple tasks and sessions. Customers can quickly identify important takeaways from their tests while alleviating the burden of lengthy post-test analysis.
Intuitively Navigate and Collaborate with UserTesting
UserTesting’s navigation redesign enables customers to access core functionalities more readily, with a new user interface, folder management, easily accessible resources, and a workspace switcher. Updates make the testing and insight management process more intuitive and accessible for broader team use, enabling scalability for growing teams across organizations. Additionally, IT departments can now manage team access more seamlessly with self-service, single sign-on, providing more governance for enterprise-scale deployments.
A Redesigned Card Sorting Experience
UserTesting has enhanced its card sorting capabilities within the UserTesting Human Insight Platform so users can view video feedback alongside card sorting metrics and gather a complete understanding of contributors’ mental models with this streamlined solution. Companies can build navigation or sitemaps based on customer expectations and behaviors, and describe categories to drive better engagement. This helps companies save costs and adapt to rapidly changing customer needs, or changes to their respective businesses, with timely feedback of how digital properties are organized and used.
En français … UserTesting
UserTesting is now available in French for both customer and contributor experiences. Companies looking to get feedback from French-speaking consumers can now do so with the UserTesting Human Insight Platform, as tests can be conducted in French, with French-speaking contributors, giving organizations the ability to target and connect with more people around the world.
Now Supports Native Video/Audio Testing
For companies wanting to test sensitive media content with greater efficiency, UserTesting enables customers to securely upload audio, video, and other media assets directly onto the Human Insight Platform with its new native media asset testing feature. Companies can gather contributor feedback easily on unreleased assets, like video and audio files, before launching them to the public.
“More than ever, it’s imperative that companies know how their customers feel, and why. UserTesting is continuously innovating its platform to help companies gain actionable insights so they can make smarter and faster business decisions,” said Kaj van de Loo, CTO at UserTesting. “UserTesting’s data-driven automation helps customers speed up analysis of video feedback, so they can make decisions quicker than ever. The platform helps companies optimize the use of human insights, so that they can better understand what is driving customer behavior, and adapt to any changes in the market.”
UserTesting will be hosting a webinar highlighting its latest product release on August 3 at 11:00 a.m. PT/2:00 p.m. ET. Register for the webinar here .
About UserTesting
UserTesting (NYSE: USER) has fundamentally changed the way organizations get insights from customers with fast, opt-in feedback and experience capture technology. The UserTesting Human Insight Platform taps into our global network of real people and generates video-based recorded experiences, so anyone in an organization can directly ask questions, hear what users say, see what they mean, and understand what it’s actually like to be a customer. Unlike approaches that track user behavior then try to infer what that behavior means, UserTesting reduces guesswork and brings customer experience data to life with human insight. UserTesting has approximately 2,500 customers, including more than half of the world’s top 100 most valuable brands according to Forbes. UserTesting is headquartered in San Francisco, California. To learn more, visit www.usertesting.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005310/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom